| Literature DB >> 25844040 |
Vanessa Chenel1, Patrick Boissy2, Marie-Sol Poirier2, Jean-Pierre Cloarec3, Johane Patenaude2.
Abstract
BACKGROUND: Despite marked optimism in the field of nanomedicine about the use of drug-delivery nanocarriers, uncertainties exist concerning nanocarriers' possible unintended impacts and effects. These uncertainties could affect user acceptance and acceptability. "Acceptance" refers to the intention to put a technology or a device to a specified use. "Acceptability" refers to a value judgment that accounts for acceptance. The objectives of this study were to characterize impact perception, acceptance, and acceptability in relation to drug-delivery nanocarriers in different contexts of use, and to explore relationships among these concepts.Entities:
Keywords: E3LS; ELSI; acceptance; impact perception; nanomedicine; researchers’ perceptions
Mesh:
Substances:
Year: 2015 PMID: 25844040 PMCID: PMC4368030 DOI: 10.2147/IJN.S78799
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Definition of main concepts, related variables, abbreviations, and operationalization
| Main concept | Conceptual definition | Related variable(s) | Abbreviation | Operationalization |
|---|---|---|---|---|
| Impact perception | Impact perception is defined as a two-dimensional examination of impacts, based on the estimated probability of occurrence (identification) of each impact and the significance assigned by the participant to each of these impacts (evaluation) | Perception index | PI | Respondents are asked to estimate on four-point Likert scales: to what extent could each positive and negative impact presented occurs (identification) and to what extent is each positive and negative impact presented significant for them (evaluation) Identification and evaluation scores are crossed and segmented into three categories – negative PI, neutral PI, and positive PI |
| Acceptance | Individual acceptance is defined as the intention by a user to use a technology or a device in a specified context of use | Individual acceptance | IndAtce | Respondents are asked to indicate on four-point Likert scales whether or not they: would use each of the two kinds of nanocarrier in each context of use (individual acceptance) and deem as desirable the widespread use of each of the two kinds of nanocarriers in each context of use (social acceptance) |
| Social acceptance corresponds to a personal assessment of the desirable level for society of development of a technology or a device for a specified use | Social acceptance | SocAtce | The four-point scores are used as is and transformed into “Accept/Do not accept” acceptance scores | |
| Acceptability | Individual acceptability refers to the value judgment that accounts for individual acceptance | Individual acceptability index | IndAI | Respondents are asked to indicate on four-point Likert scales which positive and negative impacts they take into account and to what extent, in explaining individual and social acceptance |
| Social acceptability refers to the value judgment that accounts for the assessment of the desirable level of development | Social acceptability index | SocAI | Acceptability indexes result in the sum of all impacts, segmented into three categories – negative AI, neutral AI, and positive AI | |
| Preponderant issue refers to the principal issue(s) invoked in forming the individual or social acceptability judgment | Individual preponderant issue | IndPIssue | Respondents are asked to indicate on four-point Likert scales which positive and negative impacts they take into account in explaining their individual and social acceptance | |
| Social preponderant issue | SocPIssue | The scores of all impacts for each issue are summed. The higher sums determine which issue(s) is (are) preponderant | ||
| Perceived usefulness defines the extent to which the respondent deems the technology presented to be useful | Individual perceived usefulness | Useful/Ind | Respondents are asked to indicate on four-point Likert scales, to what extent do they agree with usefulness of presented nanocarriers in each context of use, from an individual and a societal point of view | |
| Social perceived usefulness | Useful/Soc | The four-point scores are used as is |
Note: See the Supplementary materials for the complete questionnaire.
Description of issues presented with respect to use of selected nanocarriers, and impacts affecting positively or negatively these issues
| Issues | Orientation | Impacts |
|---|---|---|
| Health – how might the treatment influence the quality of human health? | Positive | Greater likelihood of cure and fewer adverse effects than with conventional methods of treatment |
| Negative | Cell toxicity caused by the accumulation of nanocapsules in the body | |
| Environment – how might the treatment influence the quality of the environment? | Positive | Greater environmental friendliness than with conventional methods of treatment |
| Negative | Contamination of the environment through the emission of nanocapsules into nature | |
| Social cohabitation – how might the treatment influence the quality of relationships among individuals? | Positive | Reduced costs to the health care system in the long run |
| Negative | Unequal patient access to this delivery method |
Comparisons between nanocarriers among perception index, individual and social acceptance, and individual and social acceptability
| PI comparisons across nanocarrier composition
| ||||||
|---|---|---|---|---|---|---|
| Carbon | DNA | Significance | ||||
| Positive | 27.10% | 38.30% | ||||
| Neutral | 39.30% | 32.70% | ||||
| Negative | 33.60% | 29.00% | ||||
|
| ||||||
| Yes | 93.50% | 90.70% | 19.20% | 19.60% | ||
| No | 6.50% | 9.30% | 80.80% | 80.40% | ||
| Yes | 92.50% | 90.20% | 20.60% | 20.60% | ||
| No | 7.50% | 9.80% | 79.40% | 79.40% | ||
| Positive | 76.20% | 76.20% | 23.80% | 23.80% | ||
| Neutral | 15.40% | 12.60% | 21.50% | 23.40% | ||
| Negative | 8.40% | 11.20% | 54.70% | 52.80% | ||
| Positive | 72.00% | 72.90% | 26.20% | 29.00% | ||
| Neutral | 19.20% | 17.30% | 26.60% | 25.20% | ||
| Negative | 8.90% | 9.80% | 47.20% | 45.80% | ||
|
| ||||||
| Yes | 93.50% | 19.20% | 90.70% | 19.60% | ||
| No | 6.50% | 80.80% | 9.30% | 80.40% | ||
| Yes | 92.50% | 20.60% | 90.20% | 20.60% | ||
| No | 7.50% | 79.40% | 9.80% | 79.40% | ||
| Positive | 76.20% | 23.80% | 76.20% | 23.80% | ||
| Neutral | 15.40% | 21.50% | 12.60% | 23.40% | ||
| Negative | 8.40% | 54.70% | 11.20% | 52.80% | ||
| Positive | 72.00% | 26.20% | 72.90% | 29.00% | ||
| Neutral | 19.20% | 26.60% | 17.30% | 25.20% | ||
| Negative | 8.90% | 47.20% | 9.80% | 45.80% | ||
Abbreviations: PI, perception index; IndAtce, individual acceptance; SocAtce, social acceptance; IndAI, individual acceptability index; SocAI, social acceptability index.
Figure 1Comparisons of individual and social preponderant issues among nanocarrier compositions and contexts of use.
Abbreviations: H|E|S, complex profile where all issues are equally preponderant; Env|Soc, complex profile where environmental and social cohabitation issues are preponderant; Hea|Soc, complex profile where health and social cohabitation issues are preponderant; Hea|Env, complex profile where health and environmental issues are preponderant.
Regression estimates of variables concerning carbon nanocarrier to treat seasonal flu
| Variables | PI | IndAtce | IndAI | SocAtce | SocAI | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Goodness-of-fit tests | ||||||||||
| 46.1 | 117.2 | 83.2 | 130.2 | 95.3 | ||||||
| Nagelkerke | 21.9% | 67.6% | 37.2% | 71.4% | 40.9% | |||||
| % accuracy in classification | 90.7% | 91.6% | ||||||||
| Significance of variables | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI |
| PI | 1.00 | 0.46/2.19 | 1.80 | 0.81/3.99 | ||||||
| Negative | 0.40 | 0.18/0.90 | 0.32 | 0.15/0.69 | ||||||
| Neutral | 0.74 | 0.37/1.50 | 0.44 | 0.22/0.89 | ||||||
| Positive | 1.00 | 1.00 | ||||||||
| IndAtce | 7.36 | 1.81/29.9 | ||||||||
| Do not accept | 1.22 | 0.43/3.46 | 0.21 | 0.07/0.61 | 0.87 | 0.29/2.57 | ||||
| Accept | 1.00 | 1.00 | 1.00 | |||||||
| IndAI | 2.52 | 1.22/5.19 | 0.81 | 0.39/1.69 | ||||||
| Negative | 0.37 | 0.17/0.81 | 0.21 | 0.10/0.46 | ||||||
| Neutral | 0.48 | 0.20/1.13 | 0.85 | 0.36/2.00 | ||||||
| Positive | 1.00 | 1.00 | ||||||||
| SocAtce | 8.02 | 1.90/33.8 | ||||||||
| Do not accept | 0.77 | 0.27/2.16 | 1.23 | 0.42/3.58 | 0.14 | 0.05/0.41 | ||||
| Accept | 1.00 | 1.00 | 1.00 | |||||||
| SocAI | 0.95 | 0.42/2.16 | 3.61 | 1.65/7.88 | ||||||
| Negative | 0.30 | 0.14/0.65 | 0.17 | 0.07/0.39 | ||||||
| Neutral | 0.28 | 0.12/0.63 | 0.72 | 0.32/1.61 | ||||||
| Positive | 1.00 | 1.00 | ||||||||
| Useful/Ind | 14.6 | 3.86/55.5 | 1.90 | 0.45/8.00 | ||||||
| No | 0.88 | 0.30/2.55 | 1.65 | 0.53/5.12 | 1.13 | 0.36/3.49 | ||||
| Yes | 1.00 | 1.00 | 1.00 | |||||||
| Useful/Soc | 1.99 | 0.50/7.92 | 13.1 | 3.74/45.7 | ||||||
| No | 0.70 | 0.27/1.77 | 0.45 | 0.17/1.18 | 0.93 | 0.35/2.50 | ||||
| Yes | 1.00 | 1.00 | 1.00 | |||||||
Note:
P<0.05.
Abbreviations: PI, perception index; IndAtce, individual acceptance; IndAI, individual acceptability index; SocAtce, social acceptance; SocAI, social acceptability index; Useful/Ind, individual perceived usefulness; Useful/Soc, social perceived usefulness; OR, odds ratio; CI, confidence interval.
Figure 2Multiple correspondence analysis: coordinates graph of core variable modalities for listed variables concerning use of carbon nanocarrier to treat seasonal flu. Notes: Modalities: − = negative; o = neutral; + = positive for PI, IndAI, and SocAI; − − = wholly disagree; − = somewhat disagree; + = somewhat agree; + + = wholly agree for IndAtce, Useful/Ind, SocAtce, and Useful/Soc.